PLRXライブシグナル | Getagraph.comで利益を最大化

買う 107762 min ago

@ $16.43

発行日: 15 2月 2024 @ 05:44

リターン: -24.02%

前回のシグナル: 2月 14 - 23:30

前回のシグナル: 売る

リターン: 5.47 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:47):

Stats
本日の出来高	104 649
平均出来高	371 556
時価総額	752.78M
EPS	$-0.690 ( 2024-03-28 )
次の収益日	( $-0.770 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.54
ATR14	$0.0180 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-23	Lefebvre Eric	Buy	42 900	Common Stock
2024-01-23	Lefebvre Eric	Buy	85 800	Stock Option (Right to Buy)
2024-01-23	Hull Hans	Buy	31 500	Common Stock
2024-01-23	Hull Hans	Buy	63 000	Stock Option (Right to Buy)
2024-01-23	Ouimette Mike	Buy	31 500	Common Stock

INSIDER POWER
67.14
Last 98 transactions
Buy: 2 502 892 \| Sell: 552 083

ボリューム相関

長: -0.15 (neutral)

短: 0.70 (moderate)

Signal:(66.753) Neutral

Pliant Therapeutics Inc 相関

10 最も正の相関
PAIC	0.955
CSII	0.935
ADMS	0.932
RESN	0.927
HSKA	0.921
ZGNX	0.918
OLMA	0.915
NATI	0.914
IPW	0.912
SVAC	0.911

10 最も負の相関
NETE	-0.945
BOCH	-0.932
MMAC	-0.914
RAVN	-0.912
SHSP	-0.879
SBBP	-0.876
CFV	-0.873
AMRB	-0.869
ORMP	-0.869
AZTA	-0.861

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Pliant Therapeutics Inc 相関 - 通貨/商品

0.84
( strong )

0.87
( strong )

0.00
( neutral )

0.87
( strong )

0.72
( moderate )

-0.90
( strong negative )

Pliant Therapeutics Inc 財務諸表

Annual	2023
収益:	$1.58M
総利益:	$-261 000 (-16.52 %)
EPS:	$-2.75

FY	2023
収益:	$1.58M
総利益:	$-261 000 (-16.52 %)
EPS:	$-2.75

FY	2022
収益:	$9.69M
総利益:	$6.00M (61.99 %)
EPS:	$-2.89

FY	2021
収益:	$7.57M
総利益:	$0.00 (0.00 %)
EPS:	$-2.71

Financial Reports:

No articles found.

Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.